If proven to be accurate, the point-of-care test could provide the NHS with a highly scalable, low-cost diagnostic tool. It ...

Shares of Qiagen have rebounded after three years following a news report that the provider of biotech workflow solutions was evaluating strategic options, which include a potential sale.